This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Use of Vaccines in Patients Receiving TREMFYA

Last Updated: 01/04/2025

SUMMARY  

  • Please refer to local labeling for relevant information on the use of vaccines in patients receiving TREMFYA.
  • No data are available on the response to live or inactive vaccines.1
  • Live vaccines should not be given while a patient is undergoing therapy with TREMFYA.1

COMPANY CORE DATA SHEET

Warnings and Precautions

Immunizations

Prior to initiating therapy with TREMFYA, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA. No data are available on the response to live or inactive vaccines.1

Interactions

Live vaccines

Live vaccines should not be given while a patient is undergoing therapy with TREMFYA.1

Literature Search

A literature search of Ovid MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 04 December 2024.

 

References

1 Data on File. Guselkumab Company Core Data Sheet v21. Janssen Research & Development, LLC. EDMS-ERI-111962822; 2024.